Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease

Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease

Abstract Background Chronic kidney disease (CKD) is a very common long-term condition and powerful risk factor for cardiovascular disease (CVD). Low-dose aspirin is of proven benefit in the secondary prevention of myocardial infarction (MI) and stroke in people with pre-existing CVD. However, in peo...

Full description

Bibliographic Details
Main Authors: Hugh Gallagher, Jennifer Dumbleton, Tom Maishman, Amy Whitehead, Michael V. Moore, Ahmet Fuat, David Fitzmaurice, Robert A. Henderson, Joanne Lord, Kathryn E. Griffith, Paul Stevens, Maarten W. Taal, Diane Stevenson, Simon D. Fraser, Mark Lown, Christopher J. Hawkey, Paul J. Roderick
Format: Article
Language:English
Published: BMC 2022-04-01
Series:Trials
Subjects:
Chronic kidney disease
Cardiovascular disease
Aspirin
Primary care
Primary prevention
Online Access:https://doi.org/10.1186/s13063-022-06132-z

Internet

https://doi.org/10.1186/s13063-022-06132-z

Similar Items